Recent Transactions

26-May-17
$415 million
United States flag
Target: 

Chromalox

United Kingdom flag
Acquiror: 
Spirax Sarco

Advised Chromalox, a leading provider of electrical products, systems and solutions for industrial process heating and temperature management, on its sale to Spirax Sarco, a global engineering group

31-Oct-17
$2.0 billion
South Africa, Switzerland flags
Target: 

Hirslanden Private Hospital Group

flag not available

Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt

22-Dec-17
$5.3 billion
United Kingdom flag
Target: 

Ladbrokes Coral Group PLC

United Kingdom flag
Acquiror: 
GVC Holdings PLC

Advised Ladbrokes Coral Group PLC, a leading multi-channel sports betting and gaming company, on a recommended offer from GVC Holdings PLC, a multi-national online sports betting and gaming company

27-Mar-18
$13.0 billion
Switzerland flag
Target: 

Novartis AG’s 36.5% stake in Consumer Health Joint Venture

United Kingdom flag
Acquiror: 
GlaxoSmithKline plc

Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture

02-May-18
$3.7 billion
Canada flag
Target: 

Concordia International Corp.

flag not available

Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt

13-May-18
$81 million
Australia flag
Target: 

GWA Group Limited’s Door and Access Controls Business

Ireland flag
Acquiror: 
Allegion plc

Advised Allegion plc, a leading global security products and solutions provider, on the acquisition of GWA Group Limited’s Door & Access Systems Business, a leading provider of door furniture and commercial locksmith services in Australia

10-Jul-18
$1.1 billion
United Kingdom flag
Target: 

The AA plc

flag not available

Advised the AA plc, the UK’s largest roadside assistance provider, on the refinancing of £825mm of its senior secured facilities

03-Dec-18
$4.0 billion
United Kingdom flag
Target: 

Assets owned by GlaxoSmithKline plc

Acquiror: 
Unilever plc / Hindustan Unilever Limited

Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited

19-Dec-18
$NA
United States flag
Target: 

Pfizer Inc. Consumer Health Business

United Kingdom flag
Acquiror: 
GlaxoSmithKline plc

Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture

17-Jun-19
$80 million
Canada flag
Target: 

Renewi Canada

Netherlands flag
Acquiror: 
Convent Capital

Advised Renewi plc, a leading waste to product company, on the sale of its Canadian operations to Convent Capital, an Amsterdam-based investment firm

10-Jul-19
$NA
Brazil flag
Target: 

ICC Brazil

Canada flag
Acquiror: 
Lallemand

Advised ICC Brazil, the leader in animal health and nutrition ingredients derived from yeast in Brazil, on establishing a long term strategic partnership with Lallemand, a global leader in the development, production and marketing of yeast, bacteria and specialty ingredients

16-Jan-20
$NA
Target: 

Daimler's Mercedes-Benz passenger car and private vans distribution operations in Colombia

United Kingdom flag
Acquiror: 
Inchcape PLC

Advised Inchcape, a leading global independent multi-brand automotive distributor, on its acquisition of the Mercedes-Benz passenger car and private vans distribution operations in Colombia from Daimler Colombia

20-Feb-20
$NA
United Kingdom flag
Target: 

Asia and US rights to Physiogel

Korea flag
Acquiror: 
LG Household & Health Care

Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd

02-Mar-20
$NA
United Kingdom flag
Target: 

Global rights (excluding North America) to ThermaCare (United Kingdom)

Italy flag
Acquiror: 
Angelini Pharma

Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma

10-Jun-20
$134 million
Saudi Arabia Flag
Target: 

Equity stake in Bupa Arabia

United Kingdom flag
Acquiror: 
Bupa Ltd.

Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia,  the largest health insurance provider in the Kingdom of Saudi Arabia

01-Jul-20
$225 million
United Kingdom flag
Target: 

Cello Health plc

United States flag
Acquiror: 
Arsenal Capital Partners

Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States

22-Sep-20
$465 million
United States flag
Target: 

Windy City Wire Cable & Technology Products

United Kingdom flag
Acquiror: 
Diploma PLC

Introduced Diploma PLC, an international group supplying specialized technical products and services, to Windy City Wire Cable & Technology Products, a leading value-add manufacturer and distributor of premium quality, low voltage wire and cable in the US

01-Oct-20
$2.6 billion
United Kingdom flag
Target: 

Rolls-Royce £2bn Fully Underwritten Rights Issue

flag not available
Acquiror: 
N/A

Advising Rolls-Royce on its Fully Underwritten £2bn Rights Issue, as part of a broader recapitalisation package

29-Dec-20
$110 million
United States flag
Target: 

Biogix, Inc.

United Kingdom flag
Acquiror: 
Alliance Pharma plc

Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc

19-Feb-21
$33 million
U.S.A., U.K. flags
Target: 

Acacia Pharma Group plc

flag not available
Acquiror: 
N/A

Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share

01-Jul-21
$180 million
United Kingdom flag
Target: 

British Council’s Indian IELTS operations

Australia flag
Acquiror: 
IDP Education Limited

Sole financial adviser to IDP Education, a co-owner and distributor of the IELTS English language test, on the acquisition of the British Council’s Indian IELTS operations

14-Jul-21
Undisclosed
Target: 

New Day Aluminum LLC

United Kingdom flag
Acquiror: 
Concord Resources Ltd.

Advised DADA Holdings on the sale of its majority stake in New Day Aluminum LLC to Concord Resources Ltd.

09-Sep-21
$2.1 billion
United Kingdom flag
Target: 

easyJet plc

flag not available
Acquiror: 
N/A

Advising and acting as joint sponsor to UK-based easyJet plc, a leading low-cost European airline carrier, on its £1.2bn fully underwritten rights issue & $400m secured RCF

28-Mar-22
Pending
~$1.4 billion
United Kingdom flag
Target: 

Theramex

United States flag
Acquiror: 
Carlyle and PAI Partners

Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners

28-Mar-22
Pending
$105 million
United Kingdom flag
Target: 

Acacia Pharma Group plc

United States flag
Acquiror: 
Eagle Pharmaceuticals, Inc.

Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise

Pages

show all